Oric Pharmaceuticals
ORIC
143 hedge funds and large institutions have $442M invested in Oric Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 49 increasing their positions, 39 reducing their positions, and 17 closing their positions.
196% more call options, than puts
Call options by funds: $74K | Put options by funds: $25K
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
26% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 39
11% more funds holding
Funds holding: 129 → 143 (+14)
4.11% more ownership
Funds ownership: 107.4% → 111.52% (+4.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
28% less capital invested
Capital invested by funds: $612M → $442M (-$170M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$18.7M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$12.2M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$7.71M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$7.02M |
| 5 |
O
OrbiMed
New York
|
+$6.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$21.7M |
| 2 |
VA
VR Adviser
New York
|
-$10.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$10.2M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$6.66M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.04M |
ORIC Hedge Fund Activity: Q1 2025 in Review
143 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2025, worth a combined $442M — down 28% from $612M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ORIC positions and 17 closed out — a net gain of 14 holders — while 49 added to existing stakes and 39 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $18.7M. The largest seller was Frazier Life Sciences Management, cutting an estimated $21.7M.
- 143 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2025, up from 129 in Q4 2024.
- Funds reported $442M of Oric Pharmaceuticals stock for Q1 2025, down 28% quarter-over-quarter.
- 31 funds opened new Oric Pharmaceuticals positions in Q1 2025 and 17 closed out, a net change of +14 holders.
- The largest Oric Pharmaceuticals buyer in Q1 2025 was Viking Global Investors, an estimated $18.7M added.
- The largest Oric Pharmaceuticals seller in Q1 2025 was Frazier Life Sciences Management, an estimated $21.7M sold.
Based on aggregated 13F filings for Q1 2025.